Resmed Ventilator
Patients should continue using devices unless instructed otherwise by their healthcare provider
The U.S. Food and Drug Administration (FDA) has issued an Early Alert regarding a potentially high-risk issue affecting certain Resmed Astral 100 and Astral 150 ventilators, warning that a component failure could cause the devices to stop delivering life-sustaining ventilation.
The affected ventilators are used in homes, hospitals, and portable settings to provide continuous or intermittent ventilatory support for adults and children weighing more than 5 kilograms. Because many patients depend on these devices to breathe, interruption of therapy could result in serious injury or death.
What Is the Problem?
According to Resmed, a component known as a supercapacitor may leak over time in certain ventilators manufactured before October 2024.
If leakage damages the printed circuit board assembly (PCBA), the ventilator may unexpectedly enter a fail-safe state, causing an immediate interruption of ventilation therapy, activation of a high-priority audible alarm, system fault messages, and the inability to restart therapy
If the device fails while in standby mode, ventilation may not begin when therapy is initiated.
Patients unable to breathe independently are at greatest risk if backup ventilation is not immediately available.
As of June 23, Resmed has reported 5 serious injuries and no deaths associated with the issue.
FDA and Resmed Recommendations
FDA emphasizes that patients should not stop using their ventilator unless instructed by their treating clinician.
Instead, patients and caregivers should continue prescribed therapy while ensuring backup ventilation equipment is immediately available, verify caregivers are trained to respond to alarms and emergencies, and wait for their healthcare provider or equipment supplier to arrange inspection or corrective action.
Healthcare providers are being instructed to identify affected ventilators, prioritize patients based on clinical risk, and implement a phased inspection and repair program.
Supply Constraints Delay Repairs
Resmed reports that replacement printed circuit boards are currently in limited supply.
Because sufficient replacement parts are not yet available to repair every affected ventilator immediately, the company is implementing a risk-based phased correction strategy, prioritizing patients at highest clinical risk first.
The shortage is also expected to reduce availability of new Astral ventilators, prompting healthcare providers to consider alternative ventilator options for new patients whenever possible.
Why It Matters
This alert highlights the challenges manufacturers and regulators face when a serious design issue affects life-sustaining medical devices.
Rather than immediately removing affected ventilators from service, FDA and Resmed determined that for many patients, continuing therapy with appropriate backup equipment is safer than discontinuing use, particularly while replacement parts remain unavailable.
The agency continues to evaluate the issue and has indicated additional corrective actions may be announced as more information becomes available.
Links
Read the FDA Early Alert here.
FDA Approves Wilserdly for Advanced Breast Cancer
Genentech’s oral estrogen receptor antagonist significantly extends progression-free survival, accompanied by FDA authorization of a liquid biopsy companion diagnostic.On November 16, 2026, the U.S. Food and Drug Administration (FDA) approved giredestrant (Wilserdly,...
FDA Pivots from Artificial Intelligence to Super Intelligence
A Regulatory Solution in Search of a ProblemFDA's implementation of a presidential terminology mandate raises questions about scientific accuracy, regulatory consistency, and the responsible use of limited public health resources.Beginning November 16, 2026, the U.S....
Science, Politics, Special Interests, and FDA Independence
Former Insiders Challenge the Administration's Health AgendaFormer FDA Commissioner Marty Makary and former Kennedy adviser Calley Means allege that political and commercial pressures interfered with federal health priorities. Their accounts raise questions about...
When Preventable Diseases Return
Diseases once brought under control through vaccination have returned with devastating consequences. Historical outbreaks in the former Soviet Union and Japan offer important lessons as the United States confronts its largest measles resurgence in decades.For...
Intersurgical 22mm Smoothbore Breathing Tubes and Systems
FDA Issues Early Alert for Intersurgical Breathing Systems Over Potential Ventilation Failure. Manufacturing defect may cause breathing tube connectors to separate during use, potentially interrupting ventilation and exposing patients to serious injury or death.The...
FDA Early Alert: Teleflex/Arrow Guidewire
Affected guidewires and catheter products may release hydrophilic polymer particles into the bloodstream, potentially causing serious injury or death. No serious injuries or deaths have been reported.The U.S. Food and Drug Administration (FDA) has issued an Early...

